by American Association for Cancer Research Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the ARAMIS phase III...
Tag: <span>Darolutamide</span>
Post
Darolutamide slows spread of castration-resistant prostate cancer
Karim Fizazi, M.D., from the Université Paris-Sud, and colleagues randomly assigned men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of ≤10 months (2:1) to receive either darolutamide (955 participants; 600 mg twice daily) or placebo (554 participants) while continuing androgen-deprivation therapy. The researchers found that in the planned primary analysis, median...